Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer

Magda Bahcall1, Mark M Awad1, Lynette M Sholl2

  • 1Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Abstract

Insights

Acquired KRAS amplification drives crizotinib resistance in MET exon 14 mutant NSCLC. Dual MET/PI3K inhibition effectively overcomes this resistance, offering a promising therapeutic strategy for non-small cell lung cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MET inhibitors are effective for MET exon 14 mutant non-small cell lung cancer (NSCLC).
  • Drug resistance limits long-term efficacy of MET inhibitors.
  • Acquired KRAS amplification is an emerging mechanism of resistance.

Purpose of the Study:

  • Characterize acquired wild-type KRAS amplification as a mechanism of crizotinib resistance in MET exon 14 mutant NSCLC.
  • Investigate the molecular signaling pathways involved in KRAS-mediated resistance.
  • Propose and evaluate a combination therapy to overcome crizotinib resistance.

Main Methods:

  • Established patient-derived cell line and xenograft (PDX) models from crizotinib-resistant tumors.
  • Analyzed molecular signaling in parental and KRAS-silenced cell lines.
  • Assessed sensitivity to ligand stimulation and quantified EGFR ligand expression.
  • Screened drug combinations for efficacy in vitro and in vivo.

Main Results:

  • KRAS amplification is a recurrent event in crizotinib-resistant MET exon 14 mutant NSCLC.
  • KRAS amplification uncouples MET from downstream effectors and induces PI3K signaling.
  • Resistance involves hypersensitivity to EGFR ligand activation and reliance on PI3K signaling.
  • Dual MET/PI3K inhibition showed superior efficacy in preclinical models.

Conclusions:

  • Acquired KRAS amplification is a key mechanism of crizotinib resistance in MET exon 14 mutant NSCLC.
  • Dual MET/PI3K inhibition is a potential therapeutic strategy to overcome this resistance.
  • Targeting KRAS-mediated resistance pathways may improve outcomes for NSCLC patients.

Related Concept Videos

Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.5K
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.6K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
6.0K